Crinetics Pharmaceuticals, Inc.
CRNXDelisted Sep 1, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001658247
Crinetics Pharmaceuticals, Inc. was delisted on Sep 1, 2026; its insiders filed their last Form 4 on Sep 1, 2026; 267 institutions reported holding it in 13F filings for Q2 2026, worth $4.63B in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 1
- Last 90 days, $120.0K in total
- 13F holders
- 267
- Q2 2026, +25 vs. previous quarter
- 13F value
- $4.63B
- Reported value at the end of Q2 2026
- Superinvestors holding
- 0
- At the end of Q2 2026
Superinvestors holding CRNX, Q2 2026
No superinvestor reported holding CRNX at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Crinetics Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 7, 2026 (view filing)4:30 PM ET | Jul 2 | 5 days | Vivaldi Coelho RogerioDirector | SSale | −3.00K | $40.00 | −$120.0K | −13.5%19.2K after | 10b5-1 |
| Jun 18, 2026 (view filing) | Jun 17 | 1 day | Okey StephanieDirector | SSale | −6.90K | $35.67 | −$246.1K | −51.9%6.40K after | 2 lots10b5-1 |
| Apr 10, 2026 (view filing) | Apr 8 | 2 days | Knight Jeff E.Chief Dev. & Operating Officer | SSale | −85.2K | $40.10 | −$3.42M | −44.7%105.3K after | 10b5-1 |
| Mar 18, 2026 (view filing) | Mar 16 | 2 days | Knight Jeff E.Chief Operating Officer | SSale | −9.91K | $37.37 | −$370.4K | −8.1%112.0K after | 2 lots10b5-1 |
| Mar 18, 2026 (view filing) | Mar 16 | 2 days | Betz Stephen F.Chief Scientific Officer | SSale | −10.6K | $37.37 | −$396.6K | −7.2%137.1K after | 2 lots10b5-1 |
| Mar 18, 2026 (view filing) | Mar 16 | 2 days | Struthers Richard ScottPresident & CEO | SSale | −22.0K | $37.37 | −$821.5K | −5.2%404.8K after | 2 lots10b5-1 |
| Mar 13, 2026 (view filing) | Mar 12 | 1 day | Vivaldi Coelho RogerioDirector | SSale | −5.00K | $36.15 | −$180.8K | −23.5%16.3K after | 2 lots10b5-1 |
| Mar 4, 2026 (view filing) | Mar 3 | 1 day | Okey StephanieDirector | SSale | −3.00K | $39.67 | −$119.0K | −18.4%13.3K after | 10b5-1 |
| Mar 4, 2026 (view filing) | Mar 3 | 1 day | Schilke TobinChief Financial Officer | SSale | −6.71K | $39.67 | −$266.3K | −7.9%78.1K after | 10b5-1 |
| Jan 7, 2026 (view filing) | Jan 5 | 2 days | Kalofonos IsabelChief Commercial Officer | SSale | −2.50K | $55.00 | −$137.5K | −75.0%834 after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Crinetics Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 15,840,219 | $592.7M | 0.03% | +80,420+0.5% | Added |
| BlackRock, Inc. | 9,758,938 | $365.2M | 0.01% | +1,280,123+15.1% | Added |
| Farallon Capital Management, L.L.C. | 8,989,098 | $336.4M | 1.97% | +651,000+7.8% | Added |
| Wellington Management Group LLP | 7,131,084 | $266.8M | 0.05% | −1,026,120−12.6% | Reduced |
| Driehaus Capital Management LLC | 6,463,551 | $241.9M | 1.40% | +67,629+1.1% | Added |
| Price T Rowe Associates Inc | 6,212,681 | $232.5M | 0.02% | +857,185+16.0% | Added |
| Vanguard Portfolio Management LLC | 4,832,614 | $180.8M | 0.01% | +194,103+4.2% | Added |
| Vanguard Capital Management LLC | 4,745,262 | $177.6M | 0.00% | +71,327+1.5% | Added |
| Jupiter Topco LLC | 4,557,689 | $170.5M | 0.07% | +4,557,689 | New |
| Geode Capital Management, LLC | 2,727,633 | $102.1M | 0.01% | +246,870+10.0% | Added |
Holders of 5% or more of CRNX
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Crinetics Pharmaceuticals, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| FMR LLC | 13G/A | 15.00%14.0M shares | +4.60 ppfrom 10.40% | Feb 7, 20253 filings | May 12, 2025 | SEC |
| Wellington Management Group LLP | 13G/A | 8.90%8.38M shares | +2.70 ppfrom 6.20% | Feb 10, 20253 filings | Nov 12, 2025 | SEC |
| Farallon Capital Partners, L.P. | 13G/A | 8.50%8.02M shares | +2.50 ppfrom 6.00% | Sep 8, 20252 filings | Feb 5, 2026 | SEC |
Congress trades
2 members of Congress reported 6 trades in Crinetics Pharmaceuticals, Inc. since 2020. Newest filings:
| Filed | Member | Type | Amount |
|---|---|---|---|
| Sep 4, 2026 | Gilbert Ray Cisneros, Jr.Democrat · House · CA | Sell | $15K-$50K |
| Apr 7, 2026 | Gilbert Ray Cisneros, Jr.Democrat · House · CA | Buy | $1K-$15K |
| May 6, 2025 | Gilbert Ray Cisneros, Jr.Democrat · House · CA | Buy | $1K-$15K |
| Apr 10, 2025 | Josh GottheimerDemocrat · House · NJ | Sell | $1K-$15K |
| Feb 11, 2025 | Gilbert Ray Cisneros, Jr.Democrat · House · CA | Buy | $1K-$15K |
Democrat · House · CA · Sep 4, 2026
Sell$15K-$50K
Democrat · House · CA · Apr 7, 2026
Buy$1K-$15K
Democrat · House · CA · May 6, 2025
Buy$1K-$15K
Democrat · House · NJ · Apr 10, 2025
Sell$1K-$15K
Democrat · House · CA · Feb 11, 2025
Buy$1K-$15K